DARA BioSciences (DARA) Reports 2010 Results and Corporate Overview
DARA BioSciences yesterday provided its 2010 annual report that was filed with the SEC on March 25, 2011 and provided a corporate overview. Highlights from the announcement included: • DARA receiving approximately $8.4 million in cash and funding commitments to continue the clinical development of its two leading drug candidates for which the Company believes provides them with sufficient cash to achieve the next series of key milestones during 2011. • Announcement of a Clinical Trial Collaboration Agreement with the Symptom Management & Drug Development, Community Oncology & Prevention Trials Group, Division of Cancer Prevention; National Cancer Institute (NCI) to…